Eli Lilly’s next-generation triple-acting obesity drug retatrutide cleared another major milestone in Phase 3, with “TRIUMPH-1” data showing sustained weight loss over 80 weeks. At the highest 12 mg dose, participants lost about 28.3% on average, compared with ~2% for placebo, with results also reaching around 30% at the top end depending on cohort adherence. Lilly positioned the program as a potential benchmark-setting therapy for broader obesity populations, including those with cardiometabolic complications. The trial enrolled 2,339 participants with obesity or overweight and followed them for 80 weeks, with a subset continuing into an extension reaching 104 weeks. Lilly reported nausea and diarrhea as common adverse events, with vomiting occurring in a smaller share of participants—side-effect patterns consistent with expectations for incretin-based medicines. Independent expert commentary in the report framed retatrutide as potentially the most potent agent within the GLP-1 class due to its triple-receptor mechanism (GLP-1, glucagon, and GIP). If the FDA views the Phase 3 package favorably, retatrutide could redefine comparative expectations versus existing obesity standards. —